AIM ImmunoTech (AIM) Interest Expenses (2010 - 2026)
AIM ImmunoTech's (AIM) quarterly Interest Expenses came in at $998000.0 in Q1 2026, up 409.18% YoY from $196000.0 in Q1 2025, and up 253.9% on a QoQ basis from $282000.0 in Q4 2025.
AIM ImmunoTech (AIM) Interest Expenses (2010 - 2026) Analysis & Trends
AIM ImmunoTech (AIM) has 17 years of Interest Expenses data on file, last reported at $998000.0 in Q1 2026.
- Quarterly Interest Expenses rose 409.18% year-over-year to $998000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $998000.0 (up 409.18% YoY) and the FY2025 annual result came in at $46.9 million, up 9.27% from the prior year.
- Interest Expenses improved to $998000.0 in Q1 2026, from $282000.0 in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $2.6 million in Q2 2024 to a low of $77000.0 in Q4 2022.
- A 5-year average of $649352.9 and a median of $219000.0 in 2024 frame the typical range for Interest Expenses.
- Annual changes were most pronounced in 2024 — Interest Expenses jumped 1218.5% — and 2025, when it plunged 92.38%.
- Tracing AIM's Interest Expenses over 5 years: stood at $77000.0 in 2022, then jumped by 77.92% to $137000.0 in 2023, then slipped by 3.65% to $132000.0 in 2024, then soared by 113.64% to $282000.0 in 2025, then soared by 253.9% to $998000.0 in 2026.
- The last three Interest Expenses figures came in at $998000.0 (Q1 2026), $282000.0 (Q4 2025), and $188000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.94 Bn | 132.09 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.59 Bn | 78.60 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 65.67 Bn | 60.49 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.81 Bn | 52.67 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 42.25 Bn | 37.15 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.76 Bn | 28.45 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.41 Bn | 10.02 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.24 Bn | 26.41 Bn | - | 93.62 Mn |
| 10 | AIM ImmunoTech | 4.45 Mn | -5.52 Mn | 21,000.00 | 295,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.62 Mn |
| Jun 30, 2026 | 3.62 Mn |
| Mar 31, 2026 | 998,000.00 |
| Mar 31, 2026 | 998,000.00 |
| Dec 31, 2025 | 282,000.00 |
| Dec 31, 2025 | 282,000.00 |
| Sep 30, 2025 | 188,000.00 |
| Sep 30, 2025 | 188,000.00 |
| Jun 30, 2025 | 2.29 Mn |
| Jun 30, 2025 | 2.29 Mn |
| Mar 31, 2025 | 196,000.00 |
| Mar 31, 2025 | 196,000.00 |
| Dec 31, 2024 | 132,000.00 |
| Dec 31, 2024 | 132,000.00 |
| Sep 30, 2024 | 219,000.00 |
| Sep 30, 2024 | 219,000.00 |
| Jun 30, 2024 | 2.64 Mn |
| Jun 30, 2024 | 2.64 Mn |
| Mar 31, 2024 | 2.57 Mn |
| Mar 31, 2024 | 2.57 Mn |